46 results on '"Morris, Michael"'
Search Results
2. Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.
3. Design Considerations in the PSMAfore Trial
4. From Concept to Regulatory Drug Approval: Lessons for Theranostics
5. SNMMI Consensus Statement on Patient Selection and Appropriate Use of177Lu-PSMA-617 Radionuclide Therapy
6. Looking at the Future of Prostate Cancer Treatment
7. SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy.
8. Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem
9. Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3
10. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging
11. Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study
12. 11C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series
13. QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE‐BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE‐ CENTER RETROSPECTIVE COHORT STUDY.
14. QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLECENTER RETROSPECTIVE COHORT STUDY.
15. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody
16. Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer
17. Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone
18. Is the “VISION” of Radioligand Therapy for Prostate Cancer becoming reality?: An Overview of the Phase III trial and the Importance for the Future of Theranostics.
19. 11C-choline PET/CT in recurrent prostate cancer: retrospective analysis in a large US patient series.
20. Imaging metastatic castration-resistant prostate cancer patients with 89Zr-DFO-MSTP2109A anti-STEAP1 antibody.
21. Healthy Tissue Uptake of 68Ga‐Prostate Specific Membrane Antigen (PSMA), 18F‐DCFPyL, 18F‐Fluoromethylcholine (FCH) and 18F‐Dihydrotestosterone (FDHT).
22. Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study
23. α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 1
24. α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 2
25. Long–Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer
26. Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer.
27. Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone.
28. Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor–Axis Imaging
29. Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer
30. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
31. A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition
32. Repeatability of Quantitative 18F-NaF PET: A Multicenter Study
33. Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics.
34. Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer.
35. Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer
36. Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
37. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
38. Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
39. Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT
40. Pharmacokinetic Assessment of the Uptake of 16β-18F-Fluoro-5α-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET
41. Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer
42. Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy
43. Pharmacokinetic Assessment of the Uptake of 16β-18F-Fluoro-5α-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET.
44. Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy.
45. PET-Based Radiation Dosimetry in Man of 18F-Fluorodihydrotestosterone, a New Radiotracer for Imaging Prostate Cancer.
46. Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.